Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors for Pancreatic Cancer Liver Metastases
NCT07333287Phase 2Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in pancreatic cancer (PC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07333287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333287.